The Influence of Executive Shareholding in Pharmaceutical Industry on Corporate Performance from the Perspective of R & D

This paper takes 138 pharmaceutical manufacturing listed companies in 2008-2018 as researchsamples, proposes hypotheses and establishes multiple regression models for empirical research, and explores the impact of executive shareholding ratio on firm performance, and between executives' holdings and R& D investment. The relationship between R& D expenditure as an intermediary variable between equity incentives and firm performance, explores the impact of executive shareholdings on firm performance through R& D investment, and provides a reference for pharmaceutical manufacturing listed companies to improve performance and maximize value.